Ian Campbell

Group Leader

Peter MacCallum Cancer Institute
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.

Year:

2025

Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.

Year:

2025

Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.

Year:

2025

Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.

Year:

2025

Low grade serous carcinoma (LGSOC) is a rare epithelial ovarian cancer with unique molecular characteristics compared to the more common tubo-ovarian high-grade serous ovarian carcinoma. Pivotal clinical trials guiding the management of epithelial ovarian cancer lack sufficient cases of LGSOC for meaningful subgroup analysis, hence overall findings cannot be extrapolated to rarer chemo-resistant subtypes such as LGSOC. Furthermore, there is a need for more effective therapies for the treatment of relapsed disease, as treatment options are limited. To address this, we conducted the largest quantitative high-throughput drug screening effort (n = 3436 compounds) in 12 patient-derived LGSOC cell lines and one normal ovary cell line to identify unexplored therapeutic avenues. Using a combination of high-throughput robotics, high-content imaging and novel data analysis pipelines, our data set identified 60 high and 19 moderate confidence hits which induced cancer cell specific cytotoxicity at the lowest compound dose assessed (0.1 µM). We also revealed a series of known ( mTOR/PI3K/AKT) and novel ( EGFR and MDM2-p53 ) drug classes in which LGSOC cell lines showed demonstrable susceptibility to.

Year:

2024

Background: The effectiveness and cost-effectiveness of genetic testing for hereditary breast and ovarian cancer largely rely on the identification and clinical management of individuals with a pathogenic variant prior to developing cancer. Simulation modelling is commonly utilised to evaluate genetic testing strategies due to its ability to synthesise collections of data and extrapolate over long time periods and large populations. Existing genetic testing simulation models use simplifying assumptions for predictive genetic testing and risk management uptake, which could impact the reliability of their estimates. Our objective was to develop a microsimulation model that accurately reflects current genetic testing and subsequent care in Australia, directly incorporating the dynamic nature of predictive genetic testing within families and adherence to cancer risk management recommendations. Methods: The populatioN gEnEtic testing MOdel (NEEMO) is a population-level microsimulation that incorporates a detailed simulation of individuals linked within five-generation family units. The genetic component includes heritable high- and moderate-risk monogenic gene variants, as well as polygenic risk. Interventions include clinical genetic services, breast screening, and risk-reducing surgery. Model validation is described, and then to illustrate a practical application, NEEMO was used to compare clinical outcomes for four genetic testing scenarios in patients newly diagnosed with breast cancer (BC) and their relatives: (1) no genetic testing, (2) current practice, (3) optimised referral for genetic testing, and (4) genetic testing for all BC. Results: NEEMO accurately estimated genetic testing utilisation according to current practice and associated cancer incidence, pathology, and survival. Predictive testing uptake in first- and second-degree relatives was consistent with known prospective genetic testing data. Optimised genetic referral and expanded testing prevented up to 9.3% of BC and 4.1% of ovarian cancers in relatives of patients with BC. Expanding genetic testing eligibility to all BC patients did not lead to improvement in life-years saved in at-risk relatives compared to optimised referral of patients eligible for testing under current criteria. Conclusions: NEEMO is an adaptable and validated microsimulation model for evaluating genetic testing strategies. It captures the real-world uptake of clinical and predictive genetic testing and recommended cancer risk management, which are important considerations when considering real-world clinical and cost-effectiveness.

Year:

2024

Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.

Year:

2024

Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P

Year:

2024

Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.

Year:

2024

Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples ( 27 ) are shown, as well as alterations in immune genes and CCNE1 . Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS 41 ) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status ( BRCA1 -type HRD; BRCA2 -type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (112)

Charlie Gourley

University of Edinburgh

UNITED KINGDOM
View details

Tomáš Zima

Head of Institute

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Kathleen Claes

Full professor

Ghent University Hospital

BELGIUM
View details

Sue K. Park

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Giuseppe Matullo

-

ITALY
View details

Lisa Wiesmüller

Professor

Ulm University

GERMANY
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Eric Hahnen

-

GERMANY
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Sara Lindström

University of Washington

UNITED STATES
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

Marco Montagna

Istituto Oncologico Veneto

ITALY
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Nikola A. Bowden

University of Newcastle Australia

AUSTRALIA
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

Nicoletta Resta

Full Professor Medical Genetics

University of Bari Aldo Moro

ITALY
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Maria Piane

Sapienza University of Rome

ITALY
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Sara González

Institut Català d'Oncologia

SPAIN
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Matthew Wakefield

University of Melbourne

AUSTRALIA
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Estrid V. Hoegdall

University of Copenhagen

DENMARK
View details

Paul Timpson

Co-Director ACRF (INCITe) Centre

Garvan Institute of Medical Research

AUSTRALIA
View details

Alexandra Martins

INSERM

FRANCE
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Marc Tischkowitz

Professor and Head of Department

University of Cambridge

UNITED KINGDOM
View details

Alexander E Volk

-

GERMANY
View details

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Lyndal Anderson

University of Western Sydney

AUSTRALIA
View details

Claus Høgdall

Professor in Clinical Gynecologic Oncology

University of Copenhagen

DENMARK
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Mariarosaria Calvello

European Institute of Oncology

ITALY
View details

anna coppa

Sapienza University of Rome

ITALY
View details

Allison DePersia

NorthShore University HealthSystem

UNITED STATES
View details

Anthony Gill

University of Sydney

AUSTRALIA
View details

Ioannis Ragoussis

Professor, Head of Genome Sciences

McGill University

CANADA
View details

Celia Greenwood

McGill University

CANADA
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Parham Minoo

Associate Clinical Professor of Pathology

University of Calgary

CANADA
View details

Florentia Fostira

National Centre for Scientific Research-Demokritos

GREECE
View details

Paolo Radice

Head of Reserach Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Marketa Janatova

Assistanf Professor and researcher

Přírodovědecká Fakulta, Univerzita Karlova

CZECH REPUBLIC
View details

Joellen Schilkdraut

Professor

Emory University

UNITED STATES
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Nicholas Hawkins

Emeritus Professor

UNSW Sydney

AUSTRALIA
View details

Setor Amuzu

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

Gareth Evans

The University of Manchester

UNITED KINGDOM
View details

Weng Khong Lim

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Barbara Pasini

Associate Professor of Medical Genetics

Università degli Studi di Torino

ITALY
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jae-Hoon Kim

Yonsei University College of Medicine

SOUTH KOREA
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

C Blake Gilks

-

CANADA
View details

Peter Fasching

-

GERMANY
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Kylie-Ann Mallitt

Senior Lecturer in Biostatistics

University of Sydney

AUSTRALIA
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Philip Crowe

Professor Surgery

University of New South Wales

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Tomasz Huzarski

Pomeranian Medical University

POLAND
View details

Byoung-Gie Kim

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dane Cheasley

Senior Research Fellow

University in Western Australia

AUSTRALIA
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Brenda Y Hernandez

University of Hawaii

UNITED STATES
View details

Alvaro Monteiro

Senior Member - Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Kylie L Gorringe

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Lidia Feliubadaló

Institut Català d'Oncologia

SPAIN
View details

Koichi Matsuda

University of Tokyo

JAPAN
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Janusz Menkiszak

Head of the University Clinic

Pomeranian Medical University

POLAND
View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Joanne Ngeow

Head

Nanyang Technological University (NTU)

SINGAPORE
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Zdenek Kleibl

Laboratory of oncogenetics (head)

Charles University, First Faculty of Medicine

CZECH REPUBLIC
View details

Paul Cohen

University of Western Australia

AUSTRALIA
View details

Nicholas Boddicker

Research Associate

Mayo Clinic

UNITED STATES
View details

Aline Talhouk

Assistant Professor

The University of British Columbia

CANADA
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details

David Lawson Morris

Professor of Surgery

University of New South Wales

AUSTRALIA
View details